Contribution To Literature:
Compared with placebo, PCSK9 inhibition with evolocumab reduced the risk of first cardiovascular events among patients with atherosclerosis or…
Effect of Evolocumab in Patients at High Cardiovascular Risk without Prior Myocardial Infarction or Stroke
